Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-β precursor protein-overexpressing cultured human muscle fibers

American Journal of Pathology

Volumn 167, Issue 2, 2005, Pages 517-526

  Fratta, Pietro ^a   Engel, W King ^a   McFerrin, Janis ^a   Davies, Kelvin J A ^b   Lin, Sharon W ^b   Askanas, Valerie ^a,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c GOOD SAMARITAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CYTOTOXIC FACTOR; GAMMA TUBULIN; HEAT SHOCK PROTEIN 70; MULTIPROTEIN COMPLEX; PROTEASOME; PROTEASOME 20SALPHA; PROTEASOME 26S; PROTEASOME INHIBITOR; TAU PROTEIN; UBIQUITIN; UNCLASSIFIED DRUG;

AGGRESOME; ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; HUMAN; HUMAN TISSUE; IMMUNODETECTION; IMMUNOPRECIPITATION; INCLUSION BODY MYOSITIS; MUSCLE FIBER CULTURE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UBIQUITINATION; CELL CULTURE; DRUG ANTAGONISM; METABOLISM; MUSCLE CELL; PATHOLOGY;

AMYLOID BETA-PROTEIN PRECURSOR; CELLS, CULTURED; HSP70 HEAT-SHOCK PROTEINS; HUMANS; MUSCLE FIBERS; MYOSITIS, INCLUSION BODY; PROTEASOME ENDOPEPTIDASE COMPLEX; TAU PROTEINS; UBIQUITIN;

EID: 24144489814     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)62994-X     Document Type: Article

References (49)

1. Askanas V, Engel WK: Proposed pathogenetic cascade of inclusion-body myositis: importance of amyloid-beta, misfolded proteins, predisposing genes, and aging. Curr Opin Rheumatol 2003, 15:737-744
2. Askanas V, Engel WK: Inclusion-body myositis: newest concepts of pathogenesis and relation to aging and Alzheimer disease. J Neuropathol Exp Neurol 2001, 60:1-14
3. Askanas V, Alvarez RB, Engel WK: Beta-amyloid precursor epitopes in muscle fibers of inclusion body myositis. Ann Neurol 1993, 34:551-560
4. Askanas V, Alvarez RB, Mirabella M, Engel WK: Use of anti-neurofilament antibody to identify paired-helical filaments in inclusion-body myositis. Ann Neurol 1996, 39:389-391
5. Fratta P, Engel W, Van Leeuwen F, Hol E, Vattemi G, Askanas V: Mutant ubiquitin UBB+1 is accumulated in sporadic inclusion-body myositis muscle fibers. Neurology 2004, 63:1114-1117
6. Vattemi G, Engel WK, McFerrin J, Askanas V: Endoplasmic reticulum stress and unfolded protein response in inclusion body myositis muscle. Am J Pathol 2004, 164:1-7
7. Borden KL: Structure/function in neuroprotection and apoptosis. Ann Neurol 1998, 44(Suppl 1):S65-S71
8. Gregori L, Fuchs C, Figueiredo-Pereira ME, Van Nostrand WE, Goldgaber D: Amyloid beta-protein inhibits ubiquitin-dependent protein degradation in vitro. J Biol Chem 1995, 270:19702-19708
9. Keck S, Nitsch R, Grune T, Ullrich O: Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J Neurochem 2003, 85:115-122
10. Lam YA, Pickart CM, Alban A, Landon M, Jamieson C, Ramage R, Mayer RJ, Layfield R: Inhibition of the ubiquitin-proteasome system in Alzheimer's disease. Proc Natl Acad Sci USA 2000, 97:9902-9906
11. Lindersson E, Beedholm R, Hojrup P, Moos T, Gai W, Hendil KB, Jensen PH: Proteasomal inhibition by alpha-synuclein filaments and oligomers. J Biol Chem 2004, 279:12924-12934
12. Lindsten K, de Vrij FM, Verhoef LG, Fischer DF, van Leeuwen FW, Hol EM, Masucci MG, Dantuma NP: Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation. J Cell Biol 2002, 157:417-427
13. Lopez Salon M, Pasquini L, Besio Moreno M, Pasquini JM, Soto E: Relationship between beta-amyloid degradation and the 263 proteasome in neural cells. Exp Neurol 2003, 180:131-143
14. Voges D, Zwickl P, Baumeister W: The 263 proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 1999, 68:1015-1068
15. Sherman MY, Goldberg AL: Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 2001, 29:15-32
16. Kloetzel PM: Antigen processing by the proteasome. Nat Rev Mol Cell Biol 2001, 2:179-187
17. Rock KL, York IA, Saric T, Goldberg AL: Protein degradation and the generation of MHC class I-presented peptides. Adv Immunol 2002, 80:1-70
18. Benaroudj N, Tarcsa E, Cascio P, Goldberg AL: The unfolding of substrates and ubiquitin-independent protein degradation by proteasomes. Biochimie 2001, 83:311-318
19. Jariel-Encontre I, Pariat M, Martin F, Carillo S, Salvat C, Piechaczyk M: Ubiquitinylation is not an absolute requirement for degradation of c-Jun protein by the 26 S proteasome. J Biol Chem 1995, 270:11623-11627
20. Shringarpure R, Grune T, Mehlhase J, Davies KJ: Ubiquitin conjugation is not required for the degradation of oxidized proteins by proteasome. J Biol Chem 2003, 278:311-318
21. Johnston JA, Ward CL, Kopito RR: Aggresomes: a cellular response to misfolded proteins. J Cell Biol 1998, 143:1883-1898
22. Kopito RR: Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 2000, 10:524-530
23. Wigley WC, Fabunmi RP, Lee MG, Marino CR, Muallem S, DeMartino GN, Thomas PJ: Dynamic association of proteasomal machinery with the centrosome. J Cell Biol 1999, 145:481-490
24. Garcia-Mata R, Gao YS, Sztul E: Hassles with taking out the garbage: aggravating aggresomes. Traffic 2002, 3:388-396
25. Junn E, Lee SS, Suhr UT, Mouradian MM: Parkin accumulation in aggresomes due to proteasome impairment. J Biol Chem 2002, 277:47870-47877
26. Tanaka M, Kim YM, Lee G, Junn E, Iwatsubo T, Mouradian MM: Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J Biol Chem 2004, 279:4625-4631
27. McNaught KS, Shashidharan P, Perl DP, Jenner P, Olanow CW: Aggresome-related biogenesis of Lewy bodies. Eur J Neurosci 2002, 16:2136-2148
28. Engel WK, Cunningham GG: Rapid examination of muscle tissue and improved trichrome method for fresh-frozen biopsy sections. Neurology 1963, 13:919-923
29. Askanas V, Engel WK, Alvarez RB: Enhanced detection of Congo-red-positive amyloid deposits in muscle fibers of inclusion body myositis and brain of Alzheimer's disease using fluorescence technique. Neurology 1993, 43:1265-1267
30. Vattemi G, Engel WK, McFerrin J, Askanas V: Cystatin C colocalizes with amyloid-beta and coimmunoprecipitates with amyloid-beta precursor protein in sporadic inclusion-body myositis muscles. J Neurochem 2003, 85:1539-1546
31. Askanas V, Engel WK, Alvarez RB, McFerrin J, Broccolini A: Novel immunolocalization of alpha-synuclein in human muscle of inclusion-body myositis, regenerating and necrotic muscle fibers, and at neuromuscular junctions. J Neuropathol Exp Neurol 2000, 59:592-598
32. Kim KS, Wen GY, Bancher C, Chen J, Sapienza V, Hong H, Wisniewski HM: Detection and quantitation of amyloid B-peptide with 2 monoclonal antibodies. Neurosci Res Commun 1990, 7:113-122
33. Nukina N, Kosik KS, Selkoe DJ: Recognition of Alzheimer paired helical filaments by monoclonal neurofilament antibodies is due to crossreaction with tau protein. Proc Natl Acad Sci USA 1987, 84:3415-3419
34. Zheng-Fischhèofer Q, Biernat J, Mandelkow EM, Illenberger S, Godemann R, Mandelkow E: Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical- filament-like conformation. Eur J Biochem 1998, 252:542-552
35. Husom AD, Peters EA, Kolling EA, Fugere NA, Thompson LV, Ferrington DA: Altered proteasome function and subunit composition in aged muscle. Arch Biochem Biophys 2004, 421:67-76
36. Meng L, Mohan R, Kwok B, Elofsson M, Sin N, Crews C: Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA 1999, 96:10403-10408
37. Demasi M, Shringarpure R, Davies KJ: Glutathiolation of the proteasome is enhanced by proteolytic inhibitors. Arch Biochem Biophys 2001, 389:254-263
38. Askanas V, Engel WK: Cultured normal and genetically abnormal human muscle. The Handbook of Clinical Neurology, Myopathies, Vol 18. Edited by Rowland LP, Di Mauro S. Amsterdam, North Holland, 1992, pp 85-116
39. Askanas V, McFerrin J, Baque S, Alvarez RB, Sarkozi E, Engel WK: Transfer of beta-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle. Proc Natl Acad Sci USA 1996, 93:1314-1319
40. Askanas V, McFerrin J, Alvarez RB, Baque S, Engel WK: Beta APP gene transfer into cultured human muscle induces inclusion-body myositis aspects. Neuroreport 1997, 8:2155-2158
41. Ferrer I, Martin B, Castano JG, Lucas JJ, Moreno D, Olive M: Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis. J Neuropathol Exp Neurol 2004, 63:484-498
42. McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW: Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol 2003, 179:38-46
43. Schmidt T, Lindenberg KS, Krebs A, Schèols L, Laccone F, Herms J, Rechsteiner M, Riess O, Landwehrmeyer GB: Protein surveillance machinery in brains with spinocerebellar ataxia type 3: redistribution and differential recruitment of 26S proteasome subunits and chaperones to neuronal intranuclear inclusions. Ann Neurol 2002, 51:302-310
44. Keller JN, Hanni KB, Markesbery WR: Impaired proteasome function in Alzheimer's disease. J Neurochem 2000, 75:436-439
45. Bence NF, Roopal MS, Kopito RS: Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001, 292:1552-1555
46. Klein WL: ADDLs & protofibrils-the missing links? Neurobiol Aging 2002, 23:231-235
47. Ellis RJ, Pinheiro TJ: Medicine: danger-misfolding proteins. Nature 2002, 416:483-484
48. Dalakas MC: The molecular and cellular pathology of inflammatory muscle diseases. Curr Opin Pharmacol 2001, 1:300-306
49. Murata K, Dalakas MC: Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies. Am J Pathol 1999, 155:453-460